|
2011 FEATURED PRESENTATIONS:
Point-Counterpoint Debate: Emerging Business Models and Key Drivers for U.S.-China Pharma R&D Partnerships
Mikael Dolsten, M.D., Ph.D.
President
PFIZER WORLDWIDE RESEARCH AND DEVELOPMENT
Li Chen, Ph.D.
CEO
HUA MEDICINE
Charles Hsu, Ph.D., MBA
Venture Partner
BAY CITY CAPITAL
Important Cross-Cultural Aspects of Conducting Business Activities in China
Wim Vandenhouweele
Executive Director, Global Vaccines & Commercial Development
MERCK & Co.
Identifying Outsourcing and Partnership Opportunities for Both Small and Large Life Science Companies R&D Projects Dr. Yuan-Hua Ding, Senior Director & Head of External R&D Innovation - Asia, PFIZER WORLDWIDE RESEARCH AND DEVELOPMENT Christopher Laing, MRCVS, Ph.D., Vice President, Science and Technology, UNIVERSITY CITY SCIENCE CENTER Drew Natenshon Head US Research Strategy and Operations, NOVARTIS VACCINES & DIAGNOSTICS
How to Sustain Life Science Research in China - Strengthening the Academic Collaboration between US and China Wei Zhou, M.D., Ph.D., Director, Molecular Epidemiology Pfizer Oncology; Co-Chair of Academic Relationships US CHINESE ANTI-CANCER ASSOCIATION David Christiani, M.D., M.P.H., M.S. Elkan Blout Professor of Environmental Genetics, Department of Environmental Health and Epidemiology, HARVARD SCHOOL OF PUBLIC HEALTH Qingyin Wei, M.D., Ph.D. Professor of Epidemiology, UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER
| 
